HDL: Still a target for new therapies?

Current Opinion in Investigational Drugs

Volumn 9, Issue 9, 2008, Pages 950-956

  Nicholls, S J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; HDL; Risk factor

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; ETC 216; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSUVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUSHING; HUMAN; NONHUMAN; PROTECTION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 50249169416     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366(9493):1267-1278.
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL et al: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 357(21):2109-2122.
3. Barr DP, Russ EM, Eder HA: Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med (1951) 11(4):480-493.
4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 79(1):8-15.
5. Gordon DJ, Rifkind BM: High-density lipoprotein - the clinical implications of recent studies. N Engl J Med (1989) 321(19):1311-1316.
6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 62(5):707-714.
7. Genest J Jr: Genetics and prevention: A new look at high-density lipoprotein cholesterol. Cardiol Rev (2002) 10(1):61-71.
8. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 357(13):1301-1310. •• An analysis of available data on the ability of HDL levels to predict cardiovascular risk in patients with low levels of LDL-C.
9. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest (1990) 85(4):1234-1241.
10. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V: High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest (1989) 60(3):455-461.
11. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol (2005) 25(11):2416-2421.
12. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Nat Acad Sci USA (1994) 91(20):9607-9611.
13. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (1991) 353(6341):265-267.
14. Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA: Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation (2001) 104(20):2447-2452.
15. Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation (2001) 103(25):3047-3050.
16. Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation (1994) 90(4):1935-1941.
17. Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res (1995) 36(2):211-228.
18. Barter PJ: Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors. Atherosclerosis Suppl (2002) 3(4):39-47.
19. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res (2004) 95(8):764-772.
20. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ: Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation (2005) 111(12):1543- 1550.
21. Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM: Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects. J Am Coll Cardiol (2008) 51(1):59-67.
22. Safeer RS, Cornell MO: The emerging role of HDL cholesterol. Is it time to focus more energy on raising high-density lipoprotein levels? Postgrad Med (2000) 108(7):87-90, 93-98.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation (2002) 106(25):3143-3421.
24. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet (2002) 360(9326):7-22.
25. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR et al: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. J Am Med Assoc (2007) 297(5):499-508. •• Raising HDL-C predicts the benefit of statin therapy in slowing the progression of coronary atherosclerosis.
26. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Mercouris BR, Pehlivanidis A, Bouloukos VI, Elisaf M: Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin (2004) 20(5):627-637.
27. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med (1987) 317(20):1237-1245.
28. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 341(6):410-418.
29. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet (2005) 366(9500):1849-1861.
30. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation (2000) 102(1):21-27.
31. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr et al: Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods. Am J Cardiol (2007) 99(12A):21i-33i.
32. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 113(12):1556-1563.
33. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol (1986) 8(6):1245-1255.
34. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J et al: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 345(22):1583-1592.
35. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 110(23):3512-3517.
36. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S: Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol (2006) 70(6):1844-1849.
37. Fazio S, Brown BG, Guyton JR, Polis A, Tomassini JE, Tershakovec AM: Efficacy and safety of ezetimibe/simvastatin coadministered with extended release niacin in patients with type IIa or IIb hyperlipidemia. J Am Coll Cardiol (2008) 51(10 Suppl 1):A325.
38. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrial.gov/ ct2/show/NCT00461630
39. Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. J Am Med Assoc (2003) 290(17):2292-2300. • This study demonstrated that infusing HDL promotes regression of coronary atherosclerosis in humans.
40. Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep (2006) 8(2):163-167.
41. Paris exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry (2002) 41(6):2089-2096.
42. Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation (1998) 97(8):780-785.
43. Milano dimer. Biochemistry (1999) 38(49):16307- 16314.
44. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med (2006) 3(3):144-153.
45. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC et al: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc (2007) 297(15):1675-1682.
46. Angelin B, Parini P, Eriksson M: Reverse cholesterol transport in man: Promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl (2002) 3(4):23-30.
47. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 105(12):1399-1402.
48. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES: Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 107(23):2944-2948.
49. Brewer HB Jr: Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J (2004) 148(1 Suppl):S14-S18.
50. Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ: Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta (1998) 1368(2):306-320.
51. Williams KJ, Werth VP, Wolff JA: Intravenously administered lecithin liposomes: A synthetic antiatherogenic lipid particle. Perspect Biol Med (1984) 27(3):417-431.
52. Navab M, Hama S, Hough G, Fogelman AM: Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation (2003) 108(14):1735-1739.
53. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 25(7):1325- 1331.
54. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM: Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med (2006) 3(10):540-547.
55. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR: Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 23(2):160-167.
56. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J: Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. J Am Med Assoc (2008) 299(23):2777-2788.
57. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406(6792):203-207.
58. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD et al: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 20(9):2106-2112.
59. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 350(15):1505- 1515.
60. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. Lancet (2007) 370(9582):153-160. • This study demonstrated that torcetrapib did not slow the progression of carotid intima-media thickness in patients with mixed dyslipidemia.
61. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT et al: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 356(16):1620-1630. • This study demonstrated that torcetrapib did not slow the progression of carotid intima-media thickness in patients with familial hypercholesterolemia.
62. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 356(13):1304-1316. • This study demonstrated that torcetrapib did not slow the progression of coronary atherosclerosis.
63. Tall AR, Yvan-Charvet L, Wang N: The failure of torcetrapib: Was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol (2007) 27(2):257-260.
64. Nicholls SJ, Brennan DM, Wolski K, Kalidindi SR, Moon K-W, Tuzcu EM, Nissen SE: Changes in levels of high-density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: Insights from ILLUSTRATE. Circulation (2007) 116:II_127.
65. Macdonald DL, Terry TL, Agellon LB, Nation PN, Francis GA: Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2003) 23(9):1583-1588.
66. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E et al: Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol (2008) 154(7):1465-1473. •• This study demonstrated the effects of torcetrapib on aldosterone levels in animal models.
67. A study assessing the effect of RO4607381 on vascular function in patients with coronary heart disease (CHD) or CHD-risk equivalent patients. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/ NCT00655538
68. Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM, Rader DJ: Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation (2003) 108(17):2121-2126.
69. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ: Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest (2003) 111(3):357-362.
70. Badellino KO, Wolfe ML, Reilly MP, Rader DJ: Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med (2006) 3(2):e22.
71. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T: Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation (2008) 117(16):2123-2130. •• Raising HDL-C predicts the benefit of pioglitazone, a PPARγ agonist, in slowing the progression of carotid intima-media thickness.
72. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J et al: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. J Am Med Assoc (2008) 299(13):1561-1573. •• Using intravascular ultrasound, this study demonstrated that pioglitazone halts the progression of coronary atherosclerosis in patients with diabetes.
73. Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, Gomez EV, Russo JM: Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials. J Am Med Assoc (2007) 297(12):1362-1373.
74. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ: Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2006) 113(1):90-97.
75. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J et al: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA (2002) 99(11):7604-7609.
76. Li AC, Glass CK: PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res (2004) 45(12):2161-2173.
77. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H et al: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 114(4):529-541. • This study demonstrated the role of myeloperoxidase-catalyzed oxidation of apoA-I in the generation of dysfunctional HDL. Inhibition of this pathway may improve the functional quality of HDL, without raising systemic HDL-C levels.
78. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 13(10):1176-1184. • This study demonstrated the role of carbamylation as a chemical pathway involved in the generation of dysfunctional HDL.
79. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML et al: Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J Am Med Assoc (2008) 299(11):1265-1276. •• This study defined the relationship between paraoxonase activity, measures of oxidative stress and cardiovascular risk, and suggested that promoting paraoxonase activity might improve the functional quality of HDL.
80. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol (2008) 51(23):2199-2211. •• An elegant description of the need to focus on the functional quality of HDL.